Vertex shares surge as its cystic fibrosis combo proves marginally positive, but payers may not be so impressed
Vertex came up with the positive data that analysts were looking for in pivotal studies of a combination drug for cystic fibrosis, teeing up new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
